Colorectal cancer remains a top killer, yet traditional screening pathways leave many behind.
Admission to GLP-1 therapy once crawled through a maze of clinic calendars, phone tag, and insurer
The shift from merely documenting the slow decline of the human body to actively engineering its rejuvenation marks one of the most profound transitions in modern scientific history. Findings presented at the latest global summits indicate that the field of gerontology is no longer content with
Modern oncology has long grappled with the frustrating reality that two patients with the exact same diagnosis can experience drastically different outcomes despite receiving identical treatments. This clinical mystery often stems from the hidden biological diversity within a single tumor, a
Ivan Kairatov has spent years at the intersection of biopharmaceutical innovation and rare disease
The pharmaceutical landscape is currently witnessing a seismic shift as Eli Lilly commits a
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
Advanced Therapy Medicinal Products cannot be scaled the same way biologics were. The core
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The landscape of rare disease drug development is littered with clinical failures. For every
Every year on April 25, the global scientific community pauses to recognize DNA Day, a date that marks the monumental publication of the double-helix structure in 1953 and the triumphant completion of the Human Genome Project in 2003. For the researchers at The Institute of Cancer Research (ICR),
Psychiatry’s most stubborn blind spot—objective tests that match the precision of cardiology or
Ivan Kairatov is a biopharma and health-tech veteran who has spent years turning clinical logic
